Comparison of ACE inhibitor (ACE-I) and AT1-receptor blocker (ARB) trials in heart failure/left ventricular dysfunction
| Trial/comparison (average follow up) | Placebo group | ACE-I group2-150 | ARB group2-150 | Odds ratio (95% CI) |
| SOLVD-T (52 weeks) | 201/1284 | 159/1285 | – | ACE-I/placebo: 0.76 (0.61 to 0.95) |
| SOLVD-T (104 weeks) | 344/1284 | 277/1285 | – | ACE-I/placebo: 0.75 (0.63 to 0.90) |
| ELITE (48 weeks) | – | 32/370 | 17/352 | – |
| RESOLVD pilot (43 weeks) | – | 4/109 | 20/327 | – |
| ELITE-2 (79 weeks) | – | 250/1574 | 280/1578 | ACE-I/ARB: 0.88 (0.73 to 1.06) |
| Combined ARB trials | – | 286/2053 | 317/2275 | ACE-I/ARB: 0.93 (0.77 to 1.10) |
| Imputed placebo2-151—ELITE 2 | – | – | – | ARB/placebo: 0.87 (0.65 to 1.16)2-152 |
| Imputed placebo2-151—combined ARB trials | – | – | – | ARB/placebo: 0.82 (0.62 to 1.09)2-153 |
↵2-150 Deaths/randomised patients.
↵2-151 Using SOLVD-T 52 week results.
↵2-152 Using SOLVD-T 104 week results: 0.86 (0.66 to 1.11).
↵2-153 Using SOLVD-T 104 week results: 0.81 (0.63 to 1.04).
SOLVD-T, treatment arm of the studies of left ventricular dysfunction2; ELITE, evaluation of losartan in the elderly trial9; RESOLVD, randomized evaluation of strategies for left ventricular dysfunction trial.12